AbbVie received positive CHMP opinions for Rinvoq in severe alopecia areata and non-segmental vitiligo, potentially expanding its EU label to two new autoimmune indications. EU member states will review these opinions with final decisions expected in the coming months.
AbbVie won positive opinions from the European Medicines Agency’s CHMP for Rinvoq in severe alopecia areata and non-segmental vitiligo, marking the first potential expansion of the JAK inhibitor into dermatology indications in Europe.
A US study of nearly 68,000 patients showed 17.7% switched from originator Humira to adalimumab biosimilars after formulary changes, while 16% of those patients reverted back; older adults, women and ankylosing spondylitis patients had the highest return rates.
AbbVie shares recently climbed 4.2% on volume above average to hit a 52-week high, driven by pipeline milestones and estimate upgrades; despite the rally, its price-to-earnings ratio remains modest relative to peers.
AbbVie agreed to acquire Apogee Therapeutics to bolster its dermatology portfolio with novel topical therapies, reinforcing its strategy to diversify beyond immunology and oncology franchises.
Zacks
